celcc including best of wclc 2015 -...

Czech Lung CancerCooperative Group

November 28 – 30, 2015Prague, Czech Republic, Clarion Congress Hotel Prague

15th Central EuropeanLung Cancer Conferenceincluding Best of WCLC 2015CELCC

P R o g R a m m e

• The fi rst approved irreversible ErbB Family Blocker

• Studied in the largest† global trial in EGFR M+ advanced NSCLC

• First line effi cacy provenvs pemetrexed/cisplatin

Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.Yang et al. Lancet Oncol. 2015; 16:141-51

* pre-defi ned sub-group of common mutations in the LUX-Lung 3 trial† N=345. PFS=progression-free survival OS=overall survival

GIOTRIF®

Step up in fi rst-line effi cacy

GIOTRIF 20mg / 30mg / 40 mg/ 50mg fi lm-coated tabletsQualitative and quantitative composition: GIOTRIF 20mg fi lm-coated tablets: One fi lm-coated tablet contains 20mg Afatinib (as dimaleate). Ex-cipient with known effect: One fi lm-coated tablet contains 118 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433). GIOTRIF 30mg fi lm-coated tablets: One fi lm-coated tablet contains 30mg Afatinib (as dimaleate). Excipient with known effect: One fi lm-coated tablet contains 176 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433), Indigo carmine (E132), GIOTRIF 40mg fi lm-coated tablets: One fi lm-coated tablet contains 40mg Afatinib (as dimaleate). Excipient with known effect: One fi lm-coated tablet contains 235 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433), Indigo carmine (E132), GIOTRIF 50mg fi lm-coated tablets: One fi lm-coated tablet contains 50mg Afatinib (as dimaleate). Excipient with known effect: One fi lm-coated tablet contains 294 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433), Indigo carmine (E132); Afatinib is a potent, selective inhibitor of the ErB-Receptorfamily. Therapeutic indications: GIOTRIF as monotherapy is indicated for the treatment of epidermal growth factor receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). Contraindications: Patient with known hypersentivity to Afatinib or to any of the excipients. Marketing authorisation holder: Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany. Medicinal product subject to medical prescription. Further warnings and precautions for administration, drug interactions and side effects can be seen in the summary of product characteristics.

GIO068/17.11.2015

1

Dear Colleagues,

On behalf of the Organizing Committee I would like to welcome you at the 15th Central European Lung Cancer Conference held from 28 until 30 November 2015 in Prague, Czech Republic. The important part of the programme is one day session “Best of World Congress on Lung Cancer, Denver, September 2015”.

Central European Lung Cancer Conferences have a long and successful history. Tradition of CELCC was established after the downfall of communism in Central Europe opening doors for the real international scientific cooperation. Central Europe (archaically “Middle Europe”) is the region lying between the variously defined areas of the Eastern and Western parts of the European continent. It is the region with world-wide highest incidence rates of lung cancer in some countries. CELCC was first established to be a scientific forum for sharing current knowledge and research on lung cancer. The aim was to develop strategies for decreasing the burden of lung cancer in the Central Europe focused on improvement in prevention, early diagnosis, multimodality therapies, chemotherapy and radiotherapy with future research cooperation. The Central European Lung Cancer Conferences have a long academic tradition for over two decades and have regularly been held in various cities of Central Europe since 1992. These multidisciplinary conferences focused on both education and scientific developments in the field of lung cancer by offering symposia, oral sessions, poster sessions and satellite symposia. The 1st CELCC, under the auspices of IASLC, was held in May of 1992 in Prague with large attendance of participants from throughout the world. The continuing conferences were held yearly or every two or three years in the following locations: Budapest, Gdansk, Ljubljana, Prague and Vienna.

The main topics of 15th CELCC• Immunology in lung cancer• Immunology for clinicians – in satellite symposium• Epidemiology and tobacco control and smoking cessation• Current multidisciplinary practice in lung cancer• Future targeted strategies in lung cancer• Best of World Congress on Lung Cancer, Denver, September 2015• Case discussion – young doctors workshop

I am sure that the 15th Central European Lung Cancer Conference will offer you an excellent scientific program and enhance co-operation. I am pleased to meet you in Prague.

Prof. Luboš Petruželka, MD, PhDConference President on behalf of the Organizing Committee

2

Organized by:Czech Lung Cancer Cooperative Group

Central European Lung Cancer Board

Conference President:Prof. Luboš Petruželka, MD, PhD, Czech Republic

Scientific Secretary:Assoc. prof. Milada Zemanová, MD, PhD, Czech Republic

Honorary Committee:Svatopluk Němeček, MD, MBA, Minister of Health of the Czech Republic

Adriana Krnáčová, Mayor of Prague

Prof. Tomáš Zima, MD, DSc, Rector of Charles University in Prague

Prof. Aleksi Šedo, MD, DSc, Dean of the First Medical Faculty of Charles University in Prague

Mgr. Dana Jurásková, PhD, MBA, Director of General University Hospital in Prague

Conference is supported by:Czech Society for Oncology of the CzMA J. E. Purkyně

Czech Pneumological and Phthisiological Society of the CzMA J. E. Purkyně

Society for Radiation Oncology, Biology and Physics of the CzMA J. E. Purkyně

15th Central European Lung Cancer Conferenceincluding Best of WCLC 2015November 28 – 30, 2015Prague, Czech Republic

Czech Lung CancerCooperative Group

Under the auspices of:International Association for the Study of Lung Cancer (IASLC)

3

International Scientific Commitee:

Central European Lung Cancer Board:

Rafal Dziadziuszko, Poland

Wilfried Eberhardt, Germany

Martin Filipits, Austria

Jacek Jassem, Poland

Jean Klastersky, Belgium

Gyula Ostoros, Hungary

Luboš Petruželka, Czech Republic

Robert Pirker, Austria

Gunta Purkalne, Latvia

Rolf Stahel, Switzerland

Johan Vansteenkiste, Belgium

Milada Zemanová, Czech Republic

Peter Beržinec, Slovakia

Christina Bogos, Hungary

Thomas Brodowicz, Austria

Tanja Cufer, Slovenia

Karin Dieckmann, Austria

Balazs Döme, Austria

Rafal Dziadziuszko, Poland

Wilfried Eberhardt, Germany

Martin Filipits, Austria

Fred Hirsch, USA

Rudolf Huber, Germany

Dragana Jovanovic, Serbia

Antonio Juretic, Croatia

Jacek Jassem, Poland

Jean Klastersky, Belgium

Walter Klepetko, Austria

Vítězslav Kolek, Czech Republic

Gábor Kovács, Hungary

Judit Moldvay, Hungary

Wlodzimierz Olsewski, Poland

Gyula Ostoros, Hungary

Branislav Perin, Serbia

Miloš Pešek, Czech Republic

Luboš Petruželka, Czech Republic

Robert Pirker, Austria

Gunta Purkalne, Latvia

Rodryg Ramlau, Poland

Aleš Ryška, Czech Republic

Nevena Secen, Serbia

Jana Skřičková, Czech Republic

Rolf Stahel, Switzerland

Jószef Tímár, Hungary

Johan Vansteenkiste, Belgium

Paul Van Houtte, Belgium

Jiří Votruba, Czech Republic

Milada Zemanová, Czech Republic

Konstantinos Zarogoulidis, Greece

Christoph Zielinski, Austria

Matjaž Zwitter, Slovenia

Under the auspices of:International Association for the Study of Lung Cancer (IASLC)

4

PRO

GR

am

mE

Ov

ERv

IEW

Tim

eSA

TURD

AY

Nov

embe

r 28,

201

5SU

ND

AY

Nov

embe

r 29,

201

5M

ON

DAY

N

ovem

ber 3

0, 2

015

Imm

unol

ogy

for c

linic

ians

Be

st o

f WCL

C I

New

s in

dia

gnos

tic

and

trea

tmen

t m

odal

itie

s

Post

er v

iew

ing,

coffe

e br

eak

Post

er v

iew

ing,

coffe

e br

eak

Lung

can

cer i

n Ce

ntra

l Eur

ope

Best

of W

CLC

IIm

ulti

disc

iplin

ary

ther

apy

of

thor

acic

can

cers

Regi

stra

tion

SaTE

LLIT

E SY

mPO

SIU

m

Boeh

ring

er In

gelh

eim

Chin

ese

– Ce

ntra

l Eur

opea

n

Sym

posi

um

Post

er v

iew

ing,

coffe

e br

eak

Coffe

e br

eak

Smok

ing

cess

atio

n w

orks

hop

Case

di

scus

sion

w

orks

hop

mol

ecul

ar a

nd C

ell

Biol

ogy

of L

ung

Canc

er

Best

of W

CLC

IIIFu

ture

str

ateg

ies

in lu

ng c

ance

r

Clos

ing

Cere

mon

y

Ope

ning

ses

sion

Coffe

e br

eak

SaTE

LLIT

E SY

mPO

SIU

mEl

i Lill

yCo

ffee

brea

k

SaTE

LLIT

E SY

mPO

SIU

mBr

isto

l-mye

rs S

quib

b

Get

-tog

ethe

r par

tyEx

hibi

tion

open

ing

Conc

ert

9 10 11 12 13 14 15 16 17 18 19 20

5

14:00 – 16:00: Smoking cessation workshopEpidemiology and tobacco control in Central Europe – IaSLC workshop to tobacco control and smoking cessation – chair and coordinator – Eva Králíková Chairpersons: G. Kovács, E. Králíková, I. Nohavová

1. Smoking and lung cancer, smoking cessation among lung cancer patientsG. Kovács, E. Pataki, Z. Cselkó, I. Horváth (Hungary)

2. Intensive treatment of tobacco dependence: 10 years Czech experienceE. Králíková, V. Felbrová, S. Kulovaná, A. Pánková, L. Štěpánková, K. Zvolská,M. Blaha (Czech Republic)

3. Smoking and oncology nursesI. Nohavová, V. Felbrová, S. Kulovaná, K. Malá, E. Roubíčková (Czech Republic)

Discussion

16:00 – 17:00: Opening sessionChairpersons: L. Petruželka, R. Pirker, J. Vansteenkiste

1. History of Central European Lung Cancer Conference – CELCCL. Petruželka (Czech Republic)

2. Basics of lung cancer immunotherapyJ. F. Vansteenkiste (Belgium)

3. Zatloukal memorial Lecture: Lung cancer: Future strategies to decrease its world-wide burdenR. Pirker (Austria)

17:00 – 17:20: Coffee break

17:20 – 19:00: Satellite symposium I – Bristol-myers SquibbNivolumab: Practice Changing in Previously Treated advanced or metastatic Squamous Cell Non-small Cell Lung Cancer

Chairpersons: L. Petruželka, V. Kolek, G. Ostoros

Epidemiology of lung cancer in Europe L. Dušek (Czech Republic)

Unmet need in squamous cell non-small cell lung cancerG. Mountzios (Greece)

SCIENTIFIC PROGRammE

Saturday, November 28, 2015

6

Immunooncology in NSCLCJ. Chorostowska-Wynimko (Poland)

Phase III study of Nivolumab vs Docetaxel in previously treated advanced or metastatic squamous cell non-small cell lung cancerL. Havel (Czech Republic)

Practical aspects of treatment with NivolumabG. Ostoros (Hungary)

Discussion

19:00: Get-together party, Exhibition opening

Saturday, November 28, 2015

7

08:00 – 09:30: Scientific session IImmunology for clinicians Chairpersons: J. Klastersky, M. Bryl, A. Ryška

1. Immunotherapy and lung cancerM. Bryl (Poland)

2. Toxicity of modern lung cancer immunotherapyJ. Klastersky, H. R. Kourie (Belgium)

3. Ongoing and future trials in lung cancer immunotherapyJ. F. Vansteenkiste (Belgium)

4. Predictive biomarkers of immune response and immunotherapyA. Ryška (Czech Republic)

09:30 – 10:00: Poster viewing, coffee break

10:00 – 12.00: Scientific session IILung cancer in Central Europe Chairpersons: M. Zemanová, T. Cufer, P. Beržinec

1. TULUNG – clinical registry of patients with non-small cell lung cancer (NSCLC)J. Skřičková, Z. Bortlíček, K. Hejduk, P. Brabec, D. Klimeš, L. Dušek (Czech Republic)

2. Oncogene-directed therapies in non-small cell lung cancer (NSCLC)T. Cufer (Slovenia)

3. Epidemiology of EGFR mutations in PolandT. Kucharczyk, P. Krawczyk (Poland)

4. Central Data Collection of management NSCLC stage III patients – ongoing study – first resultsM. Zemanová (Czech Republic), K. Dieckmann (Austria), Z. Zbožínková (Czech Republic), D. Jovanovic (Serbia), K. Bogos (Hungary), S. Chaudhary, J. Skřičková, I. Grygárková, L. Koubková, L. Petruželka (Czech Republic), R. Pirker (Austria)

5. Hormesis-threshold model for individualized lung cancer risk assessment in smoking and low-dose radiation exposureS. Zunic (Serbia)

6. Exhaled breath condensate pH in lung cancer, the impact of clinical factorsA. Bikov, Z. Lazar, N. Gyulai, M. Szentkereszty, G. Losonczy, I. Horvath, G. Galffy (Hungary)

7. Discontinuation of bevacizumab in non-progressing NSCLCP. Beržinec, M. Cerna, P. Kasan, H. Kuzmova, G. Chowaniecova, M. Martak, M. Vesela, L. Denkova, L. Dolakova, M. Kroslak, Z. Cavarova (Slovakia)

Sunday, November 29, 2015

8

12:00 – 13:30: Satellite Symposium II – Boehringer IngelheimOverall survival in NSCLC: Translating evidence into practice

Chairperson: N. Peled (Israel)

TKIs in EGFR mut+ NSCLC treatment

1. TKIs in EGFR+ NSCLC treatmentJ. Skřičková (Czech Republic)

Discussion

2. are all EGFR mutations the same? M. Hochmair (Austria)

Discussion

vargatef (nintedanib) in 2nd line NSCLC Treatment

1. angiogenesis as a target in NSCLC treatmentP. Beržinec (Slovakia)

Discussion

2. vargatef in 2nd line NSCLC treatmentM. Jakopovic (Croatia)

Discussion

Lunch will be served during the symposium


14:00 – 16:00: Scientific session IIICase discussion workshop – chair and coordinator: Jana Skřičková

Panelists: P. Beržinec, T. Cufer, M. Filipits, J. Moldvay, G. Purkalne, M. Rajer, N. Secen, J. Skřičková, M. Zemanová

Block I1. Successful treatment with afatinib: case report

Zs. Kelemen, K. Bogos (Hungary)

2. Successful treatment with Erlotinib after initial failure to find EGFR activating mutation: case report V. Kozirovskis, G. Purkalne (Latvia)

3. The effect of tyrosine kinase inhibitor erlotinib in patients with squamous cell lung cancer in the second and third line of treatment: case reportM. Šatánková, M. Tomíšková, J. Skřičková (Czech Republic)

4. Clinical case presentation: management of the EGFR-mutated patient with acquired resistance to EGFR TKIN. Turnšek Hitij, T. Cufer (Slovenia)


9

5. 22-year old patient with EmL4-aLK positive non-small lung cancer and multiple allergies T. Petrun, M. Rajer, M. Zwitter (Slovenia)

15 minutes discussion

Block II

6. adie´s pupil and aNNa-1 associated paraneoplastic neurologic syndromes predict complete response in limited-stage SCLC: case reportB. Barisic, K. B. Sreter (Croatia)

7. Secondary malignant neoplasm in the lung and the low-grade liver cancerN. Levická, G. Košturiaková, P. Vereš, V. Gál (Slovakia)

8. migratory thrombophlebitis as a first sign of lung adenocarcinomaD. Sazdanić-Velikić, I. Stojković, A. Tepavac, N. Secen (Serbia)

9. multimodality treatment of squamous cell lung cancer: case reportP. Zemanová, J. Votruba, H. Bartáková, M. Zemanová (Czech Republic)

15 minutes discussion

Parallel session (Hall Virgo): minisymposium – molecular and Cell Biology of Lung Cancer: The Implications for Prevention, Diagnostics and Therapy – coordinator: Evžen Křepela

Chairpersons: E. Křepela, M. Lewandowska, P. Vodička

1. Chromosomal damage as markers of genotoxic effect and carcinogenesisP. Vodička, Z. Polívková (Czech Republic), L. Mušák (Slovakia) M. Dušinská (Norway), S. Vodenková, V. Vymetálková, M. Kroupa, L. Vodičková, H. Demová, V. Poláková, M. Ambruš (Czech Republic), R. Kumar, K. Hemminki (Germany)

2. Transcriptional regulation of survivin gene expression in lung cancer K. Vlčková, L. Ondrušová, J. Vachtenheim, J. Réda, P. Dundr, M. Zadinová (Czech Republic)

3. Granzyme B-induced apoptosis and its regulation in lung cancer cellsE. Křepela (Czech Republic)

4. Prognostic and predictive biomarkers of lung cancerM. Lewandowska (Poland)

5. Proton pump inhibitors; a paradigm for a new strategy against cancerS. Fais (Italy)

16:00 – 16:30: Coffee break


10

16:30 – 18:00: Satellite symposium III – Eli Lilly maximizing treatment outcomes for patients with advanced NSCLC – making sense of the data

Chairperson: Luboš Petruželka

Chairperson opening remarksL. Petruželka (Czech Republic)

Treatment maximization starts with the pathologistJ. Gosney (UK)

maximizing treatment outcomes where there is a mutationV. Hirsh (Canada)

maximizing treatment outcomes in the non – mutated non squamous lung cancer patient after platinum doublet progression

M. Garassino (Italy)

Finally, new opportunities for treatment in the patient with squamous cell lung cancer

G. Ostoros (Hungary)

Putting it all into practice – patient case studiesL. Havel (Czech Republic)

Question time discussionL. Petruželka (Czech Republic)

Chairperson closing remarks and symposium evaluationL. Petruželka (Czech Republic)

19:00: Concert (New Town Hall) Not included in registration fee (price 100 CZK)


11

08:00 – 09:30: Scientific session Iv – Best of WCLC ITopic: News in diagnostic and treatment modalities

Chairpersons: W. Eberhardt, J. Vansteenkiste, J. Votruba

1. New proposals for TNm stagingW. Eberhardt (Germany)

2. News in pathology: Histological classification, pheno- and genotypic markers´ WCLC 2015J. Tímár (Hungary)

3. News in screeningJ. Votruba (Czech Republic)

4. Best of WCLC 2015: Lung cancer prevention, smoking cessation and tobacco controlE. Králíková (Czech Republic)


10:00 – 11:30: Scientific Session v – Best of WCLC IITopic: multidisciplinary therapy of thoracic cancers

Chairpersons: V. Kolek, L. Kepka, M. A. Hoda

1. adjuvant and neoadjuvant chemotherapy in NSCLCV. Kolek (Czech Republic)

2. Chemoradiotherapy in locally advanced non-small cell lung cancer: the selection of presentations from WCLC 2015L. Kepka (Poland)

3. The important advances in systemic treatment of Small-Cell Lung Cancer (SCLC)L. Petruželka, M. Zemanová, D. Sixtová, M. Miškovičová (Czech Republic)

4. News in surgeryM. A. Hoda (Austria)

12:00 – 13:30: Chinese – Central European Symposium Topic: East – West cooperation in managing of lung cancer

Chairpersons: L. Jia, M. Pešek, J. Homolka

1. The application of Traditional Chinese medicine in treatment for lung cancerLiqun Jia (China)

2. The influence of perioperative allogeneic blood transfusions to the prognosis of lung cancer patients: yes or no, why?Qun Luo (China)

monday, November 30, 2015

12

3. Common, uncommon, rare and complex EGFR mutations in Czech NSCLC patients and therapeutic effect of tyrosinkinase inhibitorsM. Pešek, V. Kolek, J. Skřičková, M. Černovská, L. Koubková, J. Roubec, F. Salajka, M. Zemanová, J. Krejčí, K. Hejduk, A. Ryška, M. Minárik, O. Fiala (Czech Republic)

4. Western medicine and Traditional Chinese medicine: is there any space for collaboration in lung cancer treatment? R. Prymula (Czech Republic)

Lunch will be served during the symposium

13:30 – 14:00: coffee break

14:00 – 15:30: Scientific session vI – Best of WCLC IIITopic: Future strategies in lung cancer

Chairpersons: F. Hirsch, R. Pirker, G. Ostoros, L. Petruželka

1. Perspectives of targeted therapyF. Hirsch (USA)

2. Next generation EGFR inhibitorsR. Dziadziuszko (Poland)

3. molecular biomarkersM. Filipits (Austria)

4. Immunotherapy of lung cancer. Best of WCLC 2015G. Ostoros (Hungary)

Panel discussion

15:30 – 16:00: Closing ceremony

monday, November 30, 2015

13

P 1: Concomitant rosuvastatin-induced rhabdomyolysis and maprotiline-associated Ogilvie syndrome in an 80-year-old female lung cancer survivor B. Barisic, K. B. Sreter, S. Popovic-Grle (Croatia)

P 2: Less frequent cause of recidive pleural effusion at higher age A. Benejová, J. Skřičková, M. Tomíšková (Czech Republic)

P 3: Salivary gland-type tumours of the lung: a two centre experience L. Brcic (Austria), S. Seiwerth (Croatia), H. Popper (Austria)

P 4: The frequency of pulmonary thromboembolism in patients with lung cancer V. Cukic, A. Ustamujic (Bosnia and Herzegovina)

P 5: Improved overall survival in patients with NSCLC treated to 36 Gy with hypofractionated radiation therapy J. Danielska, J. Chalubinska-Fendler, J. Luniewska-Bury, W. Fendler, J. Fijuth (Poland)

P 6: Change in serum lactate dehydrogenase in patients with advanced-stage NSCLC treated with erlotinib O. Fiala, M. Pešek, J. Fínek, O. Topolčan, J. Racek, M. Svatoň, O. Sorejs, M. Minárik, L. Benešová, Z. Bortlíček, R. Chloupková, A. Poprach, T. Buchler (Czech Republic)

P 7: Parenchyma sparing surgery for lung cancer in a heart transplant recipient with poor respiratory reserve J. Klein, P. Nemec, P. Pavlik, V. Hytych, P. Horazďovsky (Czech Republic)

P 8: Initiary experience with crizotinib in the treatment of NSCLC in the Czech Republic V. Kolek, M. Pešek, J. Skřičková, I. Grygárková, J. Roubec, L. Koubková, M. Černovská,

K. Hejduk, Z. Bortlíček (Czech Republic)

P 9: Experience with radical (chemo) radiotherapy in the treatment of lung cancer at Teaching Hospital Comenius University of Hradec Králové P. Malá, J. Petera, P. Paluska (Czech Republic)

P 10: Dosimetric parameters as predictive factors for radiation pneumonitis and esophagitis in patients with locally advanced Non-Small Cell Lung Cancer A. Masarykova, D. Scepanovic, P. Bires, D. Lederleitner, M. Pobijakova (Slovakia)

POSTERS

14

P 11: Therapy-related myeloid neoplasms after lung cancer chemotherapy K. Natori, D. Nagase, S. Ishihara, Y. Mitsui, A. Sakai, M. Kato, Y. Kuraishi, H. Izumi (Japan)

P 12: multiple neoplasms consist of lung cancer and hematological malignancies K. Natori, S. Ishihara, D. Nagase, Y. Mitsui, A. Sakai, M. Kato, Y. Kuraishi, H. Izumi (Japan)

P 13: The clinical, pathological and prognostic significance of cancer stem cell markers CD44 and aLDH1 expression in adenocarcinoma of the lung K. Park, W. Sung, D. Hyun (South Korea)

P 14: Salvage surgical treatment of advanced lung adenocarcinoma patient after Gefitinib therapy D. Sazdanić-Velikić, E. Budišin, I. Stojković, N. Secen (Serbia)

P 15: The platelet-to-lymphocyte ratio as a predictor of distant metastasis in lung cancer M. Serdarevic, S. Kukulj, F. Popovic, G. Drpa, B. Budimir, I. Nikolic, I. Taradi (Croatia)

P 16: Pemetrexed in maintenance therapy of 134 patients with non-small cell lung cancer (NSCLC) J. Skřičková, Z. Bortlíček, K. Hejduk, M. Pešek, V. Kolek, I. Grygárková, L. Koubková,

M. Černovská, M. Tomíšková, J. Roubec, L. Havel, F. Salajka, M. Zemanová, D. Sixtová,

H. Čoupková, M. Šatánková, M. Marel (Czech Republic)

P 17: The prognostic role of KRaS mutation in patients with advanced NSCLC treated with 2nd or 3rd line chemotherapy M. Svatoň, O. Fiala, M. Pešek, Z. Bortlíček, M. Minárik, L. Benešová (Czech Republic)

P 18: The biological and clinical significance of alpha-1 antitrypsin in non-small cell lung cancer A. Szpechcinski, E. Debek, M. Florczuk, R. Langfort, W. Kupis, P. Rudzinski, J. Zaleska,

B. Poplawska-Wisniewska, R. Struniawski, D. Giedronowicz, T. Orlowski,

K. Roszkowski-Sliz, J. Chorostowska-Wynimko (Poland)

P 19: Correlation of Gefitinib (G) efficacy and skin rash severity in locally advanced and metastatic EGFR mutated (EGFRm) non-small cell lung carcinoma (NSCLC) L. Vladimirova, A. Storozhakova, S. Kabanov, N. Abramova, E. Kalabanova (Russia)

15

Conference venueClarion Congress Hotel Prague

Freyova 33

190 00 Prague 9

Czech Republic

Phone: + 420 211 131 139

E-mail: [email protected]

Clarion Congress Hotel Prague is located at the metro station “Vysočanská” (line “B”).

LanguageThe official language of the conference is English.

Registration CounterDuring the conference, the secretariat and registration counter are located at the foyer of the Conference center of the Clarion Congress Hotel Prague with the following time schedule:

Saturday, November 28, 2015 12.00 – 19.00

Sunday, November 29, 2015 07.00 – 18.00

Monday, November 30, 2015 07.30 – 16.00

GENERaL INFORmaTION

16

Conference SecretariatConference PartnersTaussigova 1170/5182 00 Prague 8Czech RepublicPhone: + 420 224 262 109, + 420 608 408 708E-mail: [email protected]: www.conference.cz/CELCC2015

Registration Fees: after November 1, 2015Members of IASLC EUR 400 Non-members EUR 500 Trainees EUR 250

Registration fee covers free access to the scientific sessions, exhibition and refreshment at breaks and lunches.

Cancellation of Registration and Refund PolicyRequest for refund of the registration fee must be sent in writing to the conference secretariat. There is a 50 EUR fee for cancellations prior to October 31, 2015. After October 31, 2015, no refunds can be made but the complete documentation will be sent to the address of the delegate.

Cancellation fees for accommodation are presented in the online accommodation form available on the website www.conference.cz/CELCC2015. Smoking PolicyWe have a strict non-smoking policy at the 15th Central European Lung Cancer Conference. Smoking inside the conference floor is prohibited.

Conference BadgeParticipants will receive a badge upon registration. Since your personal badge is the entrance ticket to the conference, please make sure that you wear your badge at all times during all conference activities and social events.

Certificate of attendanceParticipants will receive a Certificate of Attendance certifying their attendance at the conference. This document is available at the registration counter.

Exhibition OpeningExhibition will be open on Saturday, November 28, 2015 at 19.00 during the social get-together of participants.

17

Oral PresentationsPowerPoint presentations – format 4:3 can be accepted. Speakers are kindly requested to hand in their presentations on USB. PCs in the lecture rooms are installed with the operation system Windows 10 (or younger) and are equipped with Microsoft Office 2010. Speakers can check their presentations at the Speakers preview room located at the registration counter.

Poster PresentationsPosters will be displayed continuously from Saturday to Monday. Please place your poster on the poster board in the Hall Zenit with number presented in the programme. Pins are available at the registration counter.

On Sunday, November 29, 2015, 9.30 – 10.00 and 13.30 – 14.00 and Monday, November 30, 2015, 9.30 – 10.00, the presenting authors should be available at posters to explain and discuss their contributions with interested participants.

Posters must be removed on Monday by 16.00.

City Transportation Prague has a comprehensive network of public transportation consisting of metro, trams and buses. Single tickets or travel passes can be purchased at most newspaper stands and from the coin machines at metro and some tram/bus stations.

ParkingClarion Congress Hotel Prague has its own parking lot. First three hours are free, then each hour 50 CZK. The whole day parking is 400 CZK.

InsuranceOrganizers will not accept any liability for personal injuries or loss or damage of property belonging to conference participants and accompanying persons. Kindly check your personal insurance.

CurrencyThe official currency in the Czech Republic is Czech Crown (CZK). Exchange facilities are available at the airport, in hotels, at the exchange desk of the banks and at authorized money changers. All major credit cards are accepted in most hotels, restaurants and shops. Euro is accepted in great shopping centers.

18

Get-together partySaturday, November 28, 2015, 19.00

Foyer of the Conference center of Clarion Congress Hotel Prague

ConcertSunday, November 29, 2015, 19.00

New Town Hall, Charles Square (Karlovo náměstí ) 1/23, Prague 2Not included in registration fee (price 100 CZK)

New Town Hall

Metro line B, “Karlovo Náměstí” station

SOCIaL EvENTS

19

The Organizing committee would like to express the gratitude to the following companies for their support:

PLaTINUm SPONSOR

GOLDEN SPONSORS

PaRTNERS

aCKNOWLEDGEmENTS

ALIMTA* (PEMETREXED DISODIUM) ABBREVIATED PRESCRIBING INFORMATION Presentation Type I glass vials with rubber stoppers containing pemetrexed disodium equivalent to 100 and 500 mg of pemetrexed, as a sterile white to either light yellow or green-yellow lyophilised powder. Uses Alimta in combination with cisplatin is indicated for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma. Alimta in combination with cisplatin is indicated for fi rst-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. Alimta is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer, other than predominantly squamous cell histology, in patients whose disease has not progressed immediately following platinum-based chemotherapy. Alimta is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non small cell lung cancer, other than predominantly squamous cell histology. Dosage and Administration Posology: The drug is to be administered intravenously, under the supervision of a physician qualifi ed in the use of cytotoxic anti-cancer therapy. Alimta in combination with cisplatin: The recommended dose of pemetrexed is 500 mg/m2 of body surface area (BSA), given by ten-minute infusion, on day 1 of each 21-day cycle. The recommended dose of cisplatin is 75mg/m² BSA, given by two-hour infusion, approximately 30 minutes after completion of the pemetrexed infusion on day 1 of each cycle. Adequate anti-emetic treatment and hydration for cisplatin treatment must be given. Alimta as single agent: The recommended dose of pemetrexed is 500 mg/m2 BSA, given by ten-minute infusion, on day 1 of each 21-day cycle. Pre-medication: Supplement with 1000 micrograms intramuscular vitamin B12 and oral folic acid (350 to 1000 micrograms) to reduce toxicity (for full details see Summary of Product Characteristics [SPC]). To reduce the incidence and severity of skin reactions, a corticosteroid should be given the day prior to, on the day of, and the day after pemetrexed administration - this should be equivalent to 4mg of dexamethasone administered orally twice a day. Monitoring: Monitor prior to each dose for complete blood cell count, including a differential white cell count and platelet count. Absolute neutrophil count should be ≥1,500 cells/mm3 and platelets ≥100,000 cells/mm3. Prior to each dose, collect blood chemistry tests to evaluate renal and hepatic function. Dose adjustments to pemetrexed and/or cisplatin at the start of a subsequent cycle should be based on nadir haematological counts or maximum non-haematological toxicity. If necessary, delay or withhold treatment in the presence of haematological toxicity, neurotoxicity, and/or impaired hepatic/renal function. (For full information on dose modifi cation see SPC.) Paediatric population: There is no relevant use of Alimta in the paediatric population in malignant pleural mesothelioma and non-small cell lung cancer. Renal impairment: Patients with creatinine clearance ≥45 ml/min require no dose adjustment other than those recommended for all patients. Use in patients with creatinine clearance below 45 ml/min is not recommended. See also ‘Warnings and Special Precautions’. Hepatic impairment: Patients with hepatic impairment, such as bilirubin >1.5-times the upper limit of normal and/or aminotransferase >3.0-times the upper limit of normal (hepatic metastases absent) or >5.0-times the upper limit of normal (hepatic metastases present), have not been specifi cally studied. Method of administration: Precautions should be taken before handling or administering Alimta. Alimta should be administered as an intravenous infusion over 10 minutes on the fi rst day of each 21-day cycle. For instructions on reconstitution and dilution of Alimta before administration, see SPC. Contra-indications Hypersensitivity to pemetrexed or to any of the excipients. Concomitant yellow fever vaccine. Breast-feeding. Warnings and Special Precautions Myelosuppression is usually the dose-limiting toxicity. All patients must be instructed to take folic acid and vitamin B12 as a prophylactic measure. Pre- treatment with dexamethasone (or equivalent) can reduce the incidence and severity of skin reactions. Serious renal events, including acute renal failure, have been reported with pemetrexed alone or in combination with other chemotherapeutic agents. Many of the patients in whom these occurred had underlying risk factors, including dehydration or pre-existing hypertension or diabetes. The effect of third space fl uid, such as pleural effusion or ascites, on pemetrexed is not fully defi ned. A Phase 2 study of pemetrexed in 31 solid tumour patients with stable third space fl uid demonstrated no difference in pemetrexed dose normalised plasma concentrations or clearance compared to patients without third space fl uid collections. Thus, drainage of third space fl uid collection prior to pemetrexed treatment should be considered, but may not be necessary. Serious cardiovascular events, including myocardial infarction and cerebrovascular events, have been uncommonly reported when pemetrexed is given in combination with other cytotoxic agents; most of these patients had pre-existing cardiovascular risk. Concomitant use of live attenuated vaccines is not recommended. Radiation pneumonitis has been reported in patients treated with radiation either prior, during, or subsequent to pemetrexed therapy. Pay particular attention to these patients and exercise caution with use of other radiosensitising agents. Radiation recall has been reported in patients who received radiotherapy weeks or years previously. Interactions Concomitant administration of nephrotoxic drugs and substances that are also tubularly secreted could potentially result in delayed clearance of pemetrexed. If necessary, creatinine clearance should be closely monitored. Patients must avoid taking non- steroidal anti-infl ammatory drugs (NSAIDs) with long elimination half-lives for at least 5 days prior to, on the day, and at least 2 days following pemetrexed administration. If concomitant administration of NSAIDs is necessary, patients should be monitored closely for toxicity, especially myelosuppression and gastro-intestinal toxicity. In patients with normal renal function (creatinine clearance ≥ 80ml/min), high doses of NSAIDs (such as ibuprofen >1600 mg/day) and aspirin at higher dosage (≥1.3 g daily) may decrease pemetrexed elimination and increase the occurrence of adverse events. Patients with mild to moderate renal insuffi ciency (creatinine clearance from 49 to 79 ml/min) should avoid taking NSAIDs (eg, ibuprofen) or aspirin at higher dosage, for 2 days before, on the day of, and 2 days following pemetrexed administration. In patients with mild to moderate renal insuffi ciency eligible for pemetrexed therapy, NSAIDs with long elimination half-lives should be interrupted for at least 5 days prior to, on the day of, and at least 2 days following pemetrexed administration. There is a possible interaction between oral anticoagulants and pemetrexed; therefore, increase the frequency of International Normalised Ratio (INR) monitoring if treating with oral anticoagulants. Fertility, Pregnancy and Lactation Contraception in males and females: Women of childbearing potential must use effective contraception during treatment with pemetrexed. Pemetrexed can have genetically damaging effects. Sexually mature males are advised not to father a child during the treatment and up to 6 months thereafter. Contraceptive measures or abstinence are recommended. Pregnancy: There are no data from the use of pemetrexed in pregnant women but pemetrexed, like other anti-metabolites, is suspected to cause serious birth defects when administered during pregnancy. Animal studies have shown reproductive toxicity. Pemetrexed should not be used during pregnancy unless clearly necessary, after a careful consideration of the needs of the mother and the risk for the foetus. Breastfeeding: It is not known whether pemetrexed is excreted in human milk and adverse reactions on the suckling child cannot be excluded. Breast-feeding must be discontinued during pemetrexed therapy. Fertility: Owing to the possibility of pemetrexed treatment causing irreversible infertility, men are advised to seek counselling on sperm storage before starting treatment. Driving, etc It has been reported that pemetrexed may cause fatigue. Patients should be cautioned against driving or operating machinery. Undesirable Effects Summary of the safety profi le: The most commonly reported undesirable effects related to pemetrexed, whether used as monotherapy or in combination, are bone marrow suppression, manifested as anaemia, neutropenia, leucopenia, and thrombocytopenia; and gastro-intestinal toxicities, manifested as anorexia, nausea, vomiting, diarrhoea, constipation, pharyngitis, mucositis, and stomatitis. Other undesirable effects include renal toxicities, increased aminotransferases, alopecia, fatigue, dehydration, rash, infection/sepsis, and neuropathy. Rarely seen events include Stevens-Johnson syndrome and toxic epidermal necrolysis. Rare cases of anaphylactic shock have been reported. Infections and infestations: Common: Infection. Haematological: Very common: Anaemia, leucopenia, thrombocytopenia, neutropenia. Common: Febrile neutropenia and infection without neutropenia. Uncommon: Pancytopenia. Rarely, haemolytic anaemia has been reported in patients treated with pemetrexed. Gastro-intestinal: Very common: Nausea, vomiting, stomatitis/pharyngitis, anorexia, diarrhoea, constipation. Common: Dyspepsia, abdominal pain, heartburn. Uncommon: Colitis (including bleeding, sometimes fatal, intestinal perforation, intestinal necrosis, and typhlitis). Oesophagitis/radiation oesophagitis has been reported during trials. General: Very common: Fatigue. Common: Fever, conjunctivitis, pain, oedema. Metabolism and nutrition: Common: Dehydration. Nervous system: Very common: Neuropathy - sensory. Common: Neuropathy - motor, dizziness, taste disturbance. Renal and urinary: Very common: Creatinine elevation, creatinine clearance decreased. Common: Renal failure, renal disorders. Hepatobiliary: Common: SGPT (ALT) elevation and SGOT (AST) elevation, increased GGT. Rare: Cases of hepatitis, potentially serious, have been reported during trials. Skin and subcutaneous tissue: Very common: Rash/desquamation, alopecia. Common: Urticaria, allergic reaction/hypersensitivity, erythema multiforme, pruritus. Rare: Radiation recall; bullous conditions have been reported, including Stevens-Johnson syndrome and toxic epidermal necrolysis, which in some cases were fatal. Uncommon: Cases of peripheral ischaemia, leading sometimes to extremity necrosis, have been reported. Cardiovascular and cerebrovascular: Uncommon: Myocardial infarction, angina pectoris, cerebrovascular accident, supraventricular arrhythmias, transient ischaemic attack, pulmonary embolism. (Usually when given in combination with other cytotoxic agents and with pre-existing cardiovascular risk.) Common: Chest pain. Respiratory: Uncommon: Interstitial pneumonitis with respiratory insuffi ciency (sometimes fatal), radiation pneumonitis. For full details of these and other side-effects, please see the Summary of Product Characteristics. Alimta is prescription limited drug, fully reimbursed from public health insurance in the Czech Republic. Date of last SPC revision: 10 March, 2014.

This material is intended solely for Health Care Providers.Eli Lilly ČR, s.r.o., Pobřežní 394/12, 18600 Praha 8tel.: 234664111, fax: 234664891

CZALM00270

ELI-008_ALIMTA_Inzerce_148x210_EN.indd 1 19. 11. 2015 20:10:01

CELCC

• The fi rst approved irreversible ErbB Family Blocker

• Studied in the largest† global trial in EGFR M+ advanced NSCLC

• First line effi cacy provenvs pemetrexed/cisplatin

Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.Yang et al. Lancet Oncol. 2015; 16:141-51

* pre-defi ned sub-group of common mutations in the LUX-Lung 3 trial† N=345. PFS=progression-free survival OS=overall survival

GIOTRIF®

Step up in fi rst-line effi cacy

GIOTRIF 20mg / 30mg / 40 mg/ 50mg fi lm-coated tabletsQualitative and quantitative composition: GIOTRIF 20mg fi lm-coated tablets: One fi lm-coated tablet contains 20mg Afatinib (as dimaleate). Ex-cipient with known effect: One fi lm-coated tablet contains 118 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433). GIOTRIF 30mg fi lm-coated tablets: One fi lm-coated tablet contains 30mg Afatinib (as dimaleate). Excipient with known effect: One fi lm-coated tablet contains 176 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433), Indigo carmine (E132), GIOTRIF 40mg fi lm-coated tablets: One fi lm-coated tablet contains 40mg Afatinib (as dimaleate). Excipient with known effect: One fi lm-coated tablet contains 235 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433), Indigo carmine (E132), GIOTRIF 50mg fi lm-coated tablets: One fi lm-coated tablet contains 50mg Afatinib (as dimaleate). Excipient with known effect: One fi lm-coated tablet contains 294 mg lactose (as monohydrate). List of excipients: Tablet core: Lactose monohydrate, Cellulose microcrystalline (E460), Silica colloidal anhydrous (E551), Crospovidone type A, Magnesium stearate (E470b), Film-coating: Hypromellose (E464), Macrogol 400, Titanium dioxide (E171), Talc (E553b), Polysorbate 80 (E433), Indigo carmine (E132); Afatinib is a potent, selective inhibitor of the ErB-Receptorfamily. Therapeutic indications: GIOTRIF as monotherapy is indicated for the treatment of epidermal growth factor receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s). Contraindications: Patient with known hypersentivity to Afatinib or to any of the excipients. Marketing authorisation holder: Boehringer Ingelheim International GmbH, Binger Strasse 173, D-55216 Ingelheim am Rhein, Germany. Medicinal product subject to medical prescription. Further warnings and precautions for administration, drug interactions and side effects can be seen in the summary of product characteristics.

GIO068/17.11.2015

celcc including best of wclc 2015 -...

Documents